Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: kathleen who wrote (337)	6/30/1998 5:42:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 586

Thanks for the post and link. Financially, this is exactly the kind of problem that faces CYPB: There is good positive data presented, yet the volume traded is low and there is barely any movement of the stock price. Medically, the data is encouraging for many RA patients, especially those that have responded to the Prosorba column in the past. I was under the impression, however, that the average duration of response to the Prosorba column was longer than the 34 weeks stated in the article. I sure hope that the treatment will be reimbursable since it appears that most responders will need treatment every 8-9 months. That could get expensive. Will each round of treatment be 12 weeks long (1 column per week for 12 weeks)? Any word about a reverse split? Regards.